Policy Watch: 20 Synthetic Substances Regulatory Updates — May 13, 2026
This update covers synthetic substances regulatory updates 2026 with 20 key DEA scheduling actions. These include synthetic cannabinoids, opioids, and benzodiazepine analogs. The regulatory changes highlight challenges for clinicians managing cannabis…
MMJ International Holdings Seeks Injunction to Halt CMS CBD Program
Legal challenges institutional CBD programs can disrupt patient access and create uncertainty for clinicians. MMJ International Holdings seeks an injunction to halt the CMS CBD program. Understanding these challenges helps providers prepare contingency…
Temporary Halt on THC Ban in Texas by Judge
A judge temporarily halts THC ban Texas, marking a significant legal development. This decision affects cannabis medicine and clinical practice in the state. Clinicians should monitor this evolving situation closely.
Can a THC Breathalyzer Prove DUI in Georgia? Insights & Legal Challenges
THC breathalyzer detection challenges complicate proving DUI in Georgia. Current methods detect recent cannabis use but not actual impairment. This creates legal and clinical difficulties for patients and law enforcement.
In the Mix: 9 More Articles — April 09, 2026
The psychedelics therapy pilot program is expanding as Connecticut anticipates FDA approval, signaling important regulatory shifts in 2026. This development highlights evolving drug policies relevant to cannabis and related therapies. Clinicians should…
League City, Bacliff Smoke Shop Joins Industry Lawsuit Against THC Rules
Texas hemp businesses sue state over THC rules affecting patient access and product standards. This industry lawsuit highlights regulatory challenges in hemp-derived THC products. The legal action impacts clinical decision-making and patient safety…
Understanding THC Impairment Testing Challenges in Clinical Practice
THC impairment testing challenges complicate clinical and legal assessments due to poor correlation between THC levels and functional impairment. Unlike alcohol, THC pharmacokinetics create variability in impairment detection. Understanding these…
Policy Watch: DEA Scheduling Benzodiazepines and Synthetic Drugs — April 01, 2026
This April 01, 2026 policy watch covers DEA scheduling benzodiazepines 2026 updates impacting cannabis clinical practice. The DEA's placement of several benzodiazepine analogs in Schedule I affects co-prescription protocols. These regulatory changes…
Policy Watch: 10 Regulatory Updates — March 19, 2026
This update covers DEA synthetic opioid scheduling and regulatory changes relevant to cannabis clinicians. The focus is on new Schedule I placements and their clinical implications. These regulatory updates inform patient care and research considerations.
Policy Watch: 26 Regulatory Updates — March 08, 2026
The marijuana rescheduling proposal is a key focus in the March 2026 regulatory updates. This change could impact cannabis clinical practice and research access. Marijuana rescheduling remains central to evolving federal cannabis policy.